Gilead reports problems putting tenofovir, FTC and efavirenz into one pill

This article is more than 19 years old. Click here for more recent articles on this topic

Efforts to combine tenofovir, emtricitabine (FTC) and efavirenz in one pill are still failing to produce a product that is bioequivalent to dosing the three drugs separately, Gilead Sciences announced yesterday.

Gilead began attempts to coformulate the drugs in December 2004 when it announced a joint partnership with Bristol Myers Squibb, the United States' manafacturer of efavirenz (Sustiva) to investigate creating a three-drugs-in-one-tablet combination. Gilead has already received marketing approval for Truvada, a combination tablet of tenofovir and emtricitabine, and the use of these two drugs in combination with efavirenz is recommended by the United States Department of Health and Human Services' antiretroviral treatment guidelines as one of the preferred combinations for first-line treatment.

Gilead says it is proceeding with the evaluation of up to three new formulations, developed based on bi-layer technology. This bi-layer technology involves co-formulation of Truvada and Sustiva as individually formulated layers, combined together in one tablet. Gilead will initiate the bioequivalence studies in humans and stability studies of the new formulations over the next several months.

Glossary

formulation

The physical form in which a drug is manufactured or administered. Examples of formulations include tablets, capsules, powders, and oral and injectable solutions. A drug may be available in multiple formulations.

first-line therapy

The regimen used when starting treatment for the first time.

Food and Drug Administration (FDA)

Regulatory agency that evaluates and approves medicines and medical devices for safety and efficacy in the United States. The FDA regulates over-the-counter and prescription drugs, including generic drugs. The European Medicines Agency performs a similar role in the European Union.

fixed-dose combination (FDC)

Two or more drugs contained in a single dosage form, such as a capsule or tablet. By reducing the number of pills a person must take each day, fixed-dose combination drugs may help improve adherence.

Pending the results of the planned bioequivalence studies, Gilead and Bristol-Myers Squibb anticipate filing a New Drug Application with the US Food and Drug Administration in the first half of 2006.

A once-daily fixed dose combination of the three drugs will also be of interest for use in resource-limited settings, but the registration and marketing of such a product is complicated by the fact that the marketing rights to efavirenz outside the United States and five western European countries are owned by Merck, who market efavirenz as Stocrin. Merck has issued a voluntary license to the South African pharmaceutical manufacturer Thembalami to make efavirenz for the southern African market too. Gilead announced a similar arrangement on tenofovir and Truvada manufacture and distribution in Africa with Aspen Pharmacare in April 2005.